Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cidara Therapeutics
Biotech
Cidara regains rights to flu med from Janssen, divests Rezzayo
Cidara already knew that Janssen planned to palm off their flu prophylaxis candidate to another entity. Now, it turns out that entity will be …Cidara.
James Waldron
Apr 24, 2024 4:05pm
Janssen sticks with Cidara's flu med, but plans to sell it off
Sep 6, 2023 11:39am
3 Flagship biotechs make key exec hires—Chutes & Ladders
Aug 18, 2023 9:30am
Janssen's infectious disease partners left in the lurch
Jul 21, 2023 10:14am
Cidara wins near-unanimous AdComm support despite data doubts
Jan 25, 2023 10:17am
Melinta pays Cidara $30M for antifungal pending FDA review
Jul 27, 2022 11:05am